This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, E. J. Articles by Peterson, B. A. Search for Related Content PubMed PubMed Citation Articles by Lee, E. J. Articles by Peterson, B. A.

Brief-Duration High-Intensity Chemotherapy for Patients With Small Noncleaved–Cell Lymphoma or FAB L3 Acute Lymphocytic Leukemia: Results of Cancer and Leukemia Group B Study 9251

From the Department of Medicine, the Alvin and Lois Lapidus Cancer Institute, Sinai Hospital, Baltimore, MD; Cancer and Leukemia Group B Statistical Center, Durham, NC; Georgetown University, Washington, DC; Roswell Park Memorial Institute, Buffalo; New York University Medical Center, New York, NY; Ohio State University, Columbus, OH; University of Minnesota, Minneapolis, MN; and Karmanos Cancer Institute, Wayne State University, Detroit, MI.

Address reprint requests to Charles A. Schiffer, MD, Wayne State University School of Medicine, 3990 John R, Harper Hospital, 5 Hudson, Detroit, MI 48201; email: schiffer{at}karmanos.org

PURPOSE: To define the activity and feasibility of brief-duration high-intensity chemotherapy for adults with small noncleaved, non-Hodgkin’s lymphoma (SNC) and the L3 variant of acute lymphocytic leukemia (L3 ALL).

PATIENTS AND METHODS: Seventy-five adults with either SNC or L3 ALL (median age, 44 years) were treated with an aggressive regimen that consisted of one cycle of cyclophosphamide and prednisone followed by cycles containing either ifosfamide or cyclophosphamide; high-dose methotrexate, vincristine, dexamethasone, and either doxorubicin or etoposide/cytarabine; or intrathecal triple therapy with prophylactic CNS irradiation.

RESULTS: All 24 patients with L3 ALL and the 30 of 51 patients with SNC confirmed by central histologic review were included in this analysis. Forty-three of 54 patients achieved complete response (CR) (18 of 24 with ALL and 25 of 30 with SNC), and 28 are alive and in continuous CR with a median follow-up of 5.1 years. Hematologic toxicity was profound, and nonhematologic toxicity was notable, with 10 of 75 patients treated developing significant neurologic toxicity consisting of transverse myelitis in five patients, CNS toxicity in three, and severe peripheral neuropathy in two. All patients who did not achieve CR died of the disease, and all recurrences occurred within 16 months of the end of treatment. Responses and toxicities were similar in the patients with both lymphoma and leukemia.

CONCLUSION: Aggressively delivered chemotherapy is potentially curative in as many as half of patients with SNC and the L3 ALL variant. This treatment regimen had considerable neurologic toxicity and has been modified.

Contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

This article has been cited by other articles:

				S. Schwartz, K. Borner, K. Muller, P. Martus, L. Fischer, A. Korfel, T. Auton, and E. Thiel Glucarpidase (Carboxypeptidase G2) Intervention in Adult and Elderly Cancer Patients with Renal Dysfunction and Delayed Methotrexate Elimination After High-Dose Methotrexate Therapy Oncologist, November 1, 2007; 12(11): 1299 - 1308. [Abstract] [Full Text] [PDF]

				H. Uga, C. Kuramori, A. Ohta, Y. Tsuboi, H. Tanaka, M. Hatakeyama, Y. Yamaguchi, T. Takahashi, M. Kizaki, and H. Handa A New Mechanism of Methotrexate Action Revealed by Target Screening with Affinity Beads Mol. Pharmacol., November 1, 2006; 70(5): 1832 - 1839. [Abstract] [Full Text] [PDF]

				C. Compton The cancer and leukemia group B pathology committee at 50. Clin. Cancer Res., June 1, 2006; 12(11): 3617s - 3621s. [Abstract] [Full Text] [PDF]

				C.-H. Pui and W. E. Evans Treatment of Acute Lymphoblastic Leukemia N. Engl. J. Med., January 12, 2006; 354(2): 166 - 178. [Full Text] [PDF]

				M. Divine, P. Casassus, S. Koscielny, J. Bosq, C. Sebban, C. Le Maignan, A. Stamattoulas, B. Dupriez, M. Raphael, J.-L. Pico, et al. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol Ann. Onc., December 1, 2005; 16(12): 1928 - 1935. [Abstract] [Full Text] [PDF]

				I. N. Rich and K. M. Hall Validation and Development of a Predictive Paradigm for Hemotoxicology Using a Multifunctional Bioluminescence Colony-Forming Proliferation Assay Toxicol. Sci., October 1, 2005; 87(2): 427 - 441. [Abstract] [Full Text] [PDF]

				K. A. Blum, G. Lozanski, and J. C. Byrd Adult Burkitt leukemia and lymphoma Blood, November 15, 2004; 104(10): 3009 - 3020. [Abstract] [Full Text] [PDF]